Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 133-137 , May 2005

Prevalence of antiphospholipid antibodies is not different in Chilean diabetic patients and normal individuals

  • Iván G. Palomo

      Affiliations

    • Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca, Chile
    • ,
  • Verónica E. Mujica

      Affiliations

    • Servicio de Medicina (Medical Service), Hospital Regional de Talca, Talca, Chile
    • ,
  • Marcelo L. Alarcón

      Affiliations

    • Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca, Chile
    • ,
  • Jaime G. Pereira

      Affiliations

    • Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile
    • ,
  • Marcela R. Vásquez

      Affiliations

    • Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Universidad de Talca, Casilla N° 747, Talca, Chile
    • Corresponding Author InformationCorresponding author. Tel.: +56 71 200494; fax: +56 71 200488.

Received 16 July 2003 ,Revised 3 September 2004 ,Accepted 21 September 2004.

References 

  1. Amigo MC, Khamashta MA. Antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Rheumatic Disease Clinics of North America. 2000;26:331–348
  2. Arvieux J, Darnige L, Caron C, Reber G, Bensa J, Colomb M. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thrombosis and Haemostasis. 1995;74:1120–1125
  3. Best IM, Anyadike NC, Bumpers HL. The antiphospholipid syndrome in a teenage with miscarriage, thrombosis, and diabetes mellitus. American Surgeon. 2000;66:748–750
  4. Ciarla MV, Bocciarelli A, Di Gregorio S, Tordi A, Cotroneo P, Marra G, et al. Autoantibodies and endothelial dysfunction in well-controlled, uncomplicated insulin-dependent diabetes mellitus patients. Atherosclerosis. 2001;158:241–246
  5. Exner T, Richard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. British Journal of Haematology. 1978;40:143–151
  6. Galtier-Dereure F, Biron C, Vies M, Bourgeois V, Schved J, Bringer J. Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies?. Lupus. 1998;7:469–474
  7. Gargiulo P, Goldberg J, Romani B, Schiaffini R, Ciampalini P, Faulk WP, et al. Qualitative and quantitative studies of autoantibodies to phospholipid in diabetes mellitus. Clinical and Experimental Immunology. 1999;118:30–34
  8. Giusti C. Are phospholipid-binding antibodies implicated in the pathogenesis of diabetic microangiopathy?. Medical Hypotheses. 2004;63(2):235–238
  9. Giusti C, Schiaffini R, Bosco D, Ciampalini P, Pantaleo A, Vingolo E, et al. Lupus anticoagulant positivity in insulin dependent diabetic patients: an additional risk factor in the pathogenesis of diabetic retinopathy?. British Journal of Ophthalmology. 2000;84:531–533
  10. Harris EN. Antiphospholipid antibodies. British Journal of Haematology. 1990;74:1–9
  11. Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis: a study of 25 cases and review of the literature. Haemostasis. 1985;15:254–262
  12. Loizou S, McCrea JD, Rudge AC, Reynols R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme-linked immunosorbent assay (ELISA): standardizations and quantitation of results. Clinical and Experimental Immunology. 1985;62:738–745
  13. Matsuura B, Igarashi Y, Yasuda T, Treiplett D, Koike T. Anticardiolipin antibodies recognize β2glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. Journal of Experimental Medicine. 1994;179:457
  14. Mohamed SM, Abdou MO, Assem HM, Moustafa TM, Soghier LM. Anticardiolipin antibodies in children with insulin-dependent diabetes mellitus. Metabolism. 2002;51:1148–1152
  15. Montehermoso A, Cervera R, Font J, Ramos-Casal M, Garcia-Carrasco M, Formiga F, et al. Associations of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 1999;28:326–332
  16. National Diabetes Data Group. Classification of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039–1057
  17. Olsen B, Sjolie A, Hougaard P, Johannesen J, Borch-Johnsen K, Marinelli K, et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. Journal of Diabetes and its Complications. 2000;14:295–300
  18. Palomo I, Pereira J, Alarcón M, Larrain AM, Pinochet C, Vásquez M, et al. Antiphospholipid antibodies in Chilean patients with systemic lupus erythematosus. Journal of Laboratory and Clinical Medicine. 2002;140:336–341
  19. Schleider M, Nachman R, Jaffe E, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976;48:499–509
  20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329:977–986
  21. Triplett DA. Obstetrical complications associated with antiphospholipid antibodies. In:  Coulama BC,  Faulk WP,  McIntyre JA editor. Immunological obstetrics. New York: WW Norton; 1992;p. 377–403
  22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352:837–853

PII: S1056-8727(04)00100-X

doi: 10.1016/j.jdiacomp.2004.09.004

Journal of Diabetes and Its Complications
Volume 19, Issue 3 , Pages 133-137 , May 2005

Article Tools